Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial

Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.
Read more: https://www.cnbc.com/2024/06/20/gilead-prep-lenacapavir-succeeds-in-phase-3-trial.html?source=Snapzu